title: Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice.
abstract: Pancreatic cancer remains a lethal malignancy. Despite chemotherapy or/and radiotherapy after the surgery, the improvement on the overall survival of the patients has still been minimal. To develop novel therapeutic approaches, we tried to prepare mHSP65-TTL, a candidate vaccine prepared by mixing the recombinant mycobacterial heat shock protein 65 (mHSP65) with tumor tissue lysate (TTL) of Panc02 pancreatic cancer tissue. The mHSP65-TTL were used to immune the C57BL/6 mice implanted with the Panc02 cancer cells, in combination with or without low dose cyclophosphamide (CY). The results showed that mHSP65-TTL significantly prolonged the survival of the pancreatic cancer bearing mice and low dose CY enhanced the efficacy of the mHSP65-TTL. In addition, we detected mRNA expression of RORγt and IL-17A in spleen cells of mice received mHSP65-TTL or mHSP65-TTL plus CY, and found that mHSP65-TTL up-regulated mRNA expressions of RORγt and IL-17A, CY alone or mHSP65-TTL plus CY up-regulated mRNA expressions of RORγt. The work could provide an insight into a combinational approach for the immunotherapy of pancreatic cancer.
authors.affiliation: Department of Hepatobiliary-Pancreatic Surgery, Third Hospital (China-Japan Union Hospital) of Jilin University, Changchun 130021, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Xuan
authors.affiliation: Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China.
authors.forename: Youyou
authors.initials: Y
authors.lastname: Yan
authors.affiliation: Department of Molecular Biology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China.
authors.forename: Min
authors.initials: M
authors.lastname: Wan
authors.affiliation: Department of Molecular Biology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China.
authors.forename: Xiuli
authors.initials: X
authors.lastname: Wu
authors.affiliation: Department of Hepatobiliary-Pancreatic Surgery, Third Hospital (China-Japan Union Hospital) of Jilin University, Changchun 130021, China.
authors.forename: Degang
authors.initials: D
authors.lastname: Ji
authors.affiliation: Department of Molecular Biology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China.
authors.forename: Liying
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Hepatobiliary-Pancreatic Surgery, Third Hospital (China-Japan Union Hospital) of Jilin University, Changchun 130021, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Lin
authors.affiliation: Department of Hepatobiliary-Pancreatic Surgery, Third Hospital (China-Japan Union Hospital) of Jilin University, Changchun 130021, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China. Electronic address: ylyu@jlu.edu.cn.
authors.forename: Yongli
authors.initials: Y
authors.lastname: Yu
authors.affiliation: Department of Hepatobiliary-Pancreatic Surgery, Third Hospital (China-Japan Union Hospital) of Jilin University, Changchun 130021, China. Electronic address: zxw515@sohu.com.
authors.forename: Xuewen
authors.initials: X
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D001426:Bacterial Proteins / Q000008:administration & dosage*; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D018834:Chaperonin 60 / Q000008:administration & dosage*; D045424:Complex Mixtures / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D020381:Interleukin-17 / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3 / Q000235:genetics / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000628:therapy*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000951:Antigens, Neoplasm; D001426:Bacterial Proteins; D019496:Cancer Vaccines; D018834:Chaperonin 60; D045424:Complex Mixtures; D020381:Interleukin-17; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; C074119:heat-shock protein 65, Mycobacterium; D003520:Cyclophosphamide
keywords: Cyclophosphamide; Pancreatic cancer; Th17 cells; Tumor lysates; mHSP65